Annals of Diagnostic Pathology
Volume 11, Issue 4 , Pages 241-251 , August 2007

Pseudomesotheliomatous carcinoma of the lung with a distinct morphology, immunohistochemistry, and comparative genomic hybridization profile

  • Javier Pardo, MD

      Affiliations

    • Department of Pathology, Clínica Universitaria, Universidad de Navarra, 31080 Pamplona, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 948296496; fax: +34 948296500.
    • ,
  • Wenceslao Torres, MD

      Affiliations

    • Department of Thoracic Surgery, Clínica Universitaria, Universidad de Navarra, 31080 Pamplona, Spain
    • ,
  • Ana Martinez-Peñuela, MD

      Affiliations

    • Department of Pathology, Clínica Universitaria, Universidad de Navarra, 31080 Pamplona, Spain
    • ,
  • Angel Panizo, MD

      Affiliations

    • Department of Pathology, Clínica Universitaria, Universidad de Navarra, 31080 Pamplona, Spain
    • ,
  • Enrique de Alava, MD

      Affiliations

    • Laboratory of Molecular Pathology, Centro de Investigación del Cáncer-IBMCC Universidad de Salamanca-CSIC, 31080 Pamplona, Spain
    • ,
  • Juan Luis García, MD

      Affiliations

    • Laboratory of Molecular Pathology, Centro de Investigación del Cáncer-IBMCC Universidad de Salamanca-CSIC, 31080 Pamplona, Spain

References 

  1. Harwood TR, Gracey DR, Yokoo H. Pseudomesotheliomatous carcinoma of the lung. A variant of peripheral lung cancer. Am J Clin Pathol. 1976;65:159–167
  2. Kobashi Y, Matsushima T, Irei T. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma. Respirology. 2005;10:660–665
  3. Guru PK, Phillips S, Ball MM, Das A, Singh S. Pseudomesotheliomatous presentation of primary signet ring cell carcinoma of lung. Indian J Chest Dis Allied Sci. 2005;47:209–211
  4. Attanoos RL, Gibbs AR. ‘Pseudomesotheliomatous’ carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff. Histopathology. 2003;43:444–452
  5. Attems JH, Lintner F. Pseudomesotheliomatous adenocarcinoma of the lung with rhabdoid features. Pathol Res Pract. 2001;197:841–846
  6. Shah IA, Salvatore JR, Kummet T, Gani OS, Wheeler LA. Pseudomesotheliomatous carcinoma involving pleura and peritoneum: a clinicopathologic and immunohistochemical study of three cases. Ann Diagn Pathol. 1999;3:148–159
  7. Schreiner SR, Kirkpatrick BD, Askin FB. Pseudomesotheliomatous adenocarcinoma of the lung in a patient with HIV infection. Chest. 1998;113:839–841
  8. Friedman HD, Litovsky SH, Abraham JL. Mucin-positive epithelial mesothelioma and pseudomesotheliomatous adenocarcinoma. Arch Pathol Lab Med. 1993;117:967
  9. Koss M, Travis W, Moran C, Hochholzer L. Pseudomesotheliomatous adenocarcinoma: a reappraisal. Semin Diagn Pathol. 1992;9:117–123
  10. Dessy E, Pietra GG. Pseudomesotheliomatous carcinoma of the lung. An immunohistochemical and ultrastructural study of three cases. Cancer. 1991;68:1747–1753
  11. Simonsen J. Pseudomesotheliomatous carcinoma of the lung with asbestos exposure. Am J Forensic Med Pathol. 1986;7:49–51
  12. Nishimoto Y, Ohno T, Saito K. Pseudomesotheliomatous carcinoma of the lung with histochemical and immunohistochemical study. Acta Pathol Jpn. 1983;33:415–423
  13. Lin JI, Tseng CH, Tsung SH. Pseudomesotheliomatous carcinoma of the lung. South Med J. 1980;73:655–657
  14. Broghamer WL, Collins WM, Mojsejenko IK. The cyto-histopathology of a pseudomesotheliomatous carcinoma of the lung. Acta Cytol. 1978;22:239–242
  15. Falconieri G, Zanconati F, Bussani R, Di Bonito L. Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation. Pathol Res Pract. 1995;191:1147–1152
  16. Bouvier DP, Bell B. Small cell carcinoma of the pleura. South Med J. 1989;82:1437–1438
  17. Schinkewitch PH, Gasser B, Wihlm JM, Pauli G, Quoix E. Small cell carcinoma of the pleura. A case report. Lung Cancer. 1996;16:87–94
  18. Lichter P, Joos S, Bentz M, Lampel S. Comparative genomic hybridization: uses and limitations. Semin Hematol. 2000;37:348–357
  19. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer. 1994;10:231–243
  20. Travis WD, Brambilla E, Müller-Hermelink HK, et al. Pathology and genetics: tumours of the lung, pleura, thymus and heart. Lyon: IARC; 2004;
  21. Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol. 1985;16:569–579
  22. Griese M, Baatz A, Beck J, Deubzer B. Uptake of a natural surfactant and increased delivery of small organic anions into type II pneumocytes. Am J Physiol Lung Cell Mol Physiol. 2001;281:L144–L154
  23. Dairaku M, Sueishi K, Tanaka K, Horie A. Immunohistological analysis of surfactant-apoprotein in the bronchiolo-alveolar carcinoma. Virchows Arch A Pathol Anat Histopathol. 1983;400:223–234
  24. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, Noguchi M, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol. 2005;23:3279–3287
  25. Hachiya T, Honda T, Kubo K, Sekiguchi M. Expression patterns of type II pneumocyte apical surface glycoconjugates in lung adenocarcinoma cells. Virchows Arch. 1999;434:63–69
  26. Uzaslan E, Stuempel T, Ebsen M, Freudenberg N, Nakamura S, Costabel U, et al. Surfactant protein A detection in primary pulmonary adenocarcinoma without bronchioloalveolar pattern. Respiration. 2005;72:249–253
  27. Yoo SH, Jung KC, Kim JH, Sung SW, Chung JH, Shim YS, et al. Expression patterns of markers for type II pneumocytes in pulmonary sclerosing hemangiomas and fetal lung tissues. Arch Pathol Lab Med. 2005;129:915–919
  28. Singh G, Katyal SL, Ordonez NG, Dail DH, Negishi Y, Weedn VW, et al. Type II pneumocytes in pulmonary tumors. Implications for histogenesis. Arch Pathol Lab Med. 1984;108:44–48
  29. Singh G, Scheithauer BW, Katyal SL. The pathobiologic features of carcinomas of type II pneumocytes. An immunocytologic study. Cancer. 1986;57:994–999
  30. Tsutahara S, Shijubo N, Hirasawa M, Honda Y, Satoh M, Kuroki Y. Akino T Lung adenocarcinoma with type II pneumocyte characteristics. Eur Respir J. 1993;6:135–137
  31. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005;29:633–639
  32. Salisbury JR, Darby AJ, Whimster WF. Papillary adenocarcinoma of lung with psammoma bodies: report of a case derived from type II pneumocytes. Histopathology. 1986;10:877–884
  33. Ten Have-Opbroek AA, Benfield JR, van Krieken JH, Dijkman JH. The alveolar type II cell is a pluripotential stem cell in the genesis of human adenocarcinomas and squamous cell carcinomas. Histol Histopathol. 1997;12:319–336
  34. Ordonez NG. Mesothelioma/adenocarcinoma antibodies. Am J Surg Pathol. 1997;21:1399–1408
  35. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma. Am J Surg Pathol. 1997;21:1409–1419
  36. Carella R, Deleonardi G, D'Errico A, Salerno A, Egarter-Vigl E, Seebacher C, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma. A study with logistic regression analysis. Am J Surg Pathol. 2000;25:43–50
  37. Yaziji H, Battifora H, Barry TS, Hwang HC, Bacchi CE, McIntosh MW, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19:514–523
  38. Ochs M, Johnen G, Muller KM, Wahlers T, Hawgood S, Richter J, et al. Intracellular and intraalveolar localization of surfactant protein A (SP-A) in the parenchymal region of the human lung. Am J Respir Cell Mol Biol. 2002;26:91–98
  39. Aida S, Tamai S, Sekiguchi S, Shimizu N. Distribution of epidermal growth factor and epidermal growth factor receptor in human lung: immunohistochemical and immunoelectron-microscopic studies. Respiration. 1994;61:161–166
  40. Chailleux E, Dabouis G, Pioche D, et al. Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. Chest. 1988;93:159–162
  41. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non–small-cell lung cancer. J Clin Oncol. 2004;22:1103–1109
  42. Michelland S, Gazzeri S, Brambilla E, Robert-Nicoud M. Comparison of chromosomal imbalances in neuroendocrine and non–small-cell lung carcinomas. Cancer Genet Cytogenet. 1999;114:2–30
  43. Tai AL, Yan WS, Fang Y, Xie D, Sham JS, Guan XY. Recurrent chromosomal imbalances in nonsmall cell lung carcinoma: the association between 1q amplification and tumor recurrence. Cancer. 2004;100:1918–1927
  44. Ullmann R, Petzmann S, Sharma A, Cagle PT, Popper HH. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol. 2001;32:1059–1063
  45. Dardick I, A1-Jabi M, McCaughey WT, et al. Ultrastructure of poorly differentiated diffuse epithelial mesotheliomas. Ultrastruct Pathol. 1984;7:151–160
  46. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med. 2005;129:1407–1414
  47. Fehrenbach H, Wahlers T, Ochs M, Brasch F, Schmiedl A, Hirt SW, et al. Ultrastructural pathology of the alveolar type II pneumocytes of human donor lungs. Electron microscopy, stereology, and microanalysis. Virchows Arch. 1998;432:229–239
  48. Schmiedl A, Ochs M, Muhlfeld C, Johnen G, Brasch F. Distribution of surfactant proteins in type II pneumocytes of newborn, 14-day old, and adult rats: an immunoelectron microscopic and stereological study. Histochem Cell Biol. 2005;124:465–476
  49. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003;27:150–158
  50. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418–1428
  51. Frierson HF, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34:605–609
  52. Darvishian F, Roberts B, Teichberg S, Steven HI. Ultrastructural comparison of “alveolar” and “solid” areas in bronchioloalveolar carcinoma. Ann Clin Lab Sci. 2002;32:225–230
  53. Sasatomi E, Johnson LR, Aldeeb DN, Lomago DM, Thompson JW, Swalsky PA, et al. Genetic profile of cumulative mutational damage associated with early pulmonary adenocarcinoma: bronchioloalveolar carcinoma vs. stage I invasive adenocarcinoma. Am J Surg Pathol. 2004;28:1280–1288
  54. Skinnider BF, Jones EC. Renal oncocytoma and chromophobe renal cell carcinoma. A comparison of colloidal iron staining and electron microscopy. Am J Clin Pathol. 1999;111:796–803

PII: S1092-9134(06)00102-X

doi: 10.1016/j.anndiagpath.2006.08.009

Annals of Diagnostic Pathology
Volume 11, Issue 4 , Pages 241-251 , August 2007

Article Tools

* Image Usage & Resolution